PI3K抑制剂ZSTK474增强水泡性口炎病毒Δ51在骨肉瘤中的抗肿瘤作用

doi:10.16098/j.issn.0529-1356.2022.04.013

解剖学报 ›› 2022, Vol. 53 ›› Issue (4): 498-506.doi: 10.16098/j.issn.0529-1356.2022.04.013

PI3K抑制剂ZSTK474增强水泡性口炎病毒Δ51在骨肉瘤中的抗肿瘤作用

刘立柱¹ 李超艺^1* 林诗炜¹ 曲野¹ 汤强²

1.海南医学院第二附属医院创伤外科，海口 570311; 2.海南医学院海南省肿瘤发生与干预重点实验室，海口 571199

收稿日期:2020-08-10 修回日期:2020-11-08 出版日期:2022-08-06 发布日期:2022-09-11
通讯作者: 李超艺 E-mail:li35499015@126.com
基金资助:
海南省卫生健康行业科研项目;吴阶平医学基金会临床科研专项资助基金

PI3K inhibitor ZSTK474 enhancing the antitumor of vesicular stomatitis virus Δ51 against osteosarcoma

LIU Li-zhu¹ LI Chao-yi^1* LIN Shi-wei¹ QU Ye¹ TANG Qiang ²#br#

1.Department of Trauma Surgery, the Second Affiliated Hospital of Hainan Medical College, Haikou 570311,China; 2.Hainan Key Laboratory of Oncology and Intervention, Hainan Medical College, Haikou 571199, China

Received:2020-08-10 Revised:2020-11-08 Online:2022-08-06 Published:2022-09-11
Contact: LI Chao-yi E-mail:li35499015@126.com

摘要/Abstract

摘要： 目的探讨PI3K抑制剂联合溶瘤病毒是否对骨肉瘤具有溶瘤作用。方法通过MTT法检测细胞活性，寻找可以增强水泡性口炎病毒Δ51（VSVΔ51）抗肿瘤活性的抑制剂；通过电子显微镜观察内质网肿胀以及Western blotting检测凋亡相关蛋白的表达情况，探讨其增强溶瘤活性的机制；通过裸鼠移植瘤模型抑瘤实验验证PI3K抑制剂ZSTK474联合溶瘤病毒VSVΔ51疗法的肿瘤清除能力，并通过免疫组织化学实验验证肿瘤细胞凋亡情况。结果 PI3K抑制剂可以作为溶瘤病毒VSVΔ51的增效剂，其通过加强肿瘤细胞内质网应激促进骨肉瘤细胞凋亡（P＜0.01）。体内实验也表明，PI3K抑制剂联合溶瘤病毒VSVΔ51可以显著增加对骨肉瘤的溶瘤效果（P＜0.001），而且这种联合疗法增强了肿瘤中免疫细胞的浸润（P＜0.001）。结论 PI3K抑制剂联合溶瘤病毒是一种潜在的骨肉瘤治疗方法。

关键词: 骨肉瘤, 溶瘤病毒, 水泡性口炎病毒Δ51, 磷脂酰肌醇-3激酶抑制剂, 免疫印迹法, 小鼠

Abstract:

Objective To explore whether PI3K inhibitor combined with oncolytic virus can play an effective oncolytic effect on osteosarcoma. Methods The cytotoxicity to tumor cells was detected by MTT method, and the mechanism of enhancing the anti-tumor activity was explored by observation of the swelling of endoplasmic reticulum using electron microscope and the expression of apoptosis-related proteins using Western blotting. The tumor clearance ability of the combination of the PI3k inhibitor ZSTK474 and vesicular stomatitis virus Δ51 (VSVΔ51) was verified by anti-tumor experiment in vivo. The apoptosis of tumor cells was verified by immunohistochemistry. Results PI3K inhibitor could be used as sensitizers of oncolytic VSVΔ51, and confirmed that they promoted the strong apoptosis of osteosarcoma cells by aggravating the stress of endoplasmic reticulum in tumor cells (P＜0.01). In vivo experiments also showed that PI3K inhibitors combined with VSVΔ51 could significantly promote the oncolytic effect of osteosarcoma (P＜0.001), and this combination therapy enhanced the infiltration of immune cells in the tumor (P＜0.001). Conclusion PI3K inhibitors combined with oncolytic virus is a potential therapy for osteosarcoma.

Key words: Osteosarcoma, Oncolytic virus, Vesicular stomatitis virus Δ51, Phosphatidylinositol 3-kinase inhibitor, Western blotting, Mouse

中图分类号:

R730.5

刘立柱李超艺林诗炜曲野汤强. PI3K抑制剂ZSTK474增强水泡性口炎病毒Δ51在骨肉瘤中的抗肿瘤作用[J]. 解剖学报, 2022, 53(4): 498-506.

LIU Li-zhu LI Chao-yi LIN Shi-wei QU Ye TANG Qiang . PI3K inhibitor ZSTK474 enhancing the antitumor of vesicular stomatitis virus Δ51 against osteosarcoma[J]. Acta Anatomica Sinica, 2022, 53(4): 498-506.

参考文献

［1］Song K, Song J, Lin K，et al.Survival analysis of patients with metastatic osteosarcoma: a surveillance, epidemiology, and end results population-based study ［J］. Int Orthop, 2019, 43 (8):1983-1991.

［2］Brady SW, Ma X, Bahrami A, et al.The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment ［J］. Mol Cancer Res, 2019, 17 (4):895-906.

［3］Zou P, Tang R, Luo M.Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: a systematic review and meta-analysis ［J］. Int Immunopharmacol, 2019, 78:106050.

［4］Coffin R.Interview with robert coffin, inventor of t-vec: the first oncolytic immunotherapy approved for the treatment of cancer ［J］. Immunotherapy, 2016, 8 (2):103-106.

［5］Kimpel J, Urbiola C, Koske I, et al.The oncolytic virus vsv-gp is effective against malignant melanoma ［J］. Viruses, 2018, 10 (3):108.

［6］Stojdl DF, Lichty BD, tenOever BR, et al.Vsv strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents ［J］. Cancer Cell, 2003, 4 (4):263-275.

［7］Malinzi J, Ouifki R, Eladdadi A, et al.Enhancement of chemotherapy using oncolytic virotherapy: mathematical and optimal control analysis ［J］. Math Biosci Eng, 2018, 15 (6):1435-1463.

［8］Rahmani F, Ziaeemehr A, Shahidsales S, et al.Role of regulatory mirnas of the pi3k/akt/mtor signaling in the pathogenesis of hepatocellular carcinoma ［J］. J Cell Physiol, 2020, 235(5):4146-4152.

［9］Kanaizumi H, Higashi C, Tanaka Y, et al.PI3K/Akt/mTOR signalling pathway activation in patients with er-positive, metachronous, contralateral breast cancer treated with hormone therapy ［J］. Oncol Lett, 2019, 17 (2):1962-1968.

［10］Mahoney DJ, Lefebvre C, Allan K, et al.Virus-tumor interactome screen reveals er stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death ［J］. Cancer Cell, 2011, 20 (4):443-456.

［11］Ben Yebdri F, Van Grevenynghe J, Tang VA, et al.Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis ［J］. Mol Ther, 2013, 21 (11):2043-2053.

［12］Kiyuna T, Tome Y, Miyake K, et al.Eribulin suppressed cisplatinum- and doxorubicin-resistant recurrent lung metastatic osteosarcoma in a patient-derived orthotopic xenograft mouse model ［J］. Anticancer Res, 2019, 39 (9):4775-4779.

［13］Blake Z, Marks DK, Gartrell RD, et al.Complete intracranial response to talimogene laherparepvec (t-vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition ［J］. J Immunother Cancer, 2018, 6 (1):25.

［14］Bommareddy PK, Patel A, Hossain S, et al.Talimogene laherparepvec (t-vec) and other oncolytic viruses for the treatment of melanoma ［J］. Am J Clin Dermatol, 2017, 18 (1):1-15.

［15］Harrington KJ, Puzanov I, Hecht JR, et al.Clinical development of talimogene laherparepvec (t-vec): a modified herpes simplex virus type-1-derived oncolytic immunotherapy ［J］. Expert Rev Anticancer Ther, 2015, 15 (12):1389-1403.

［16］Denton NL, Chen CY, Hutzen B, et al.Myelolytic treatments enhance oncolytic herpes virotherapy in models of ewing sarcoma by modulating the immune microenvironment ［J］. Mol Ther Oncolytics, 2018, 11:62-74. 

［17］SM OB, Mathis JM.Oncolytic virotherapy for breast cancer treatment ［J］. Curr Gene Ther, 2018, 18 (4):192-205.

［18］Larabi A, Barnich N, Nguyen HTT.New insights into the interplay between autophagy, gut microbiota and inflammatory responses in ibd ［J］. Autophagy, 2020,16(1):38-51.

［19］Stepanenko AA, Chekhonin VP. Recent advances in oncolytic virotherapy and immunotherapy for glioblastoma: a glimmer of hope in the search for an effective therapy ［J］ ? Cancers (Basel), 2018, 10 (12):492.

［20］Yuan P, Dong L, Cheng Q, et al.Prototype foamy virus elicits complete autophagy involving the er stress-related upr pathway ［J］. Retrovirology, 2017, 14 (1):16.

［21］Namatame N, Tamaki N, Yoshizawa Y, et al.Antitumor profile of the pi3k inhibitor zstk474 in human sarcoma cell lines ［J］. Oncotarget, 2018, 9 (80):35141-35161.

［22］Killock D.Skin cancer: T-vec oncolytic viral therapy shows promise in melanoma ［J］. Nat Rev Clin Oncol, 2015, 12 (8):438.

[1]	洪晓敏李三强崔钦奕郑润月杨孟利罗仁利李前辉 . 酒精性肝纤维化核因子κB信号通路与性别的差异 [J]. 解剖学报, 2024, 55(1): 55-61.
[2]	魏茜茜李超红赵晨露唐家萍刘玉珍. 大鼠颈上神经节中Ⅰ组代谢型谷氨酸受体表达及慢性间歇性低氧对其的影响 [J]. 解剖学报, 2024, 55(1): 3-9.
[3]	袁蕾杨智伟杨惠刘政海何洁万炜. 三七总皂苷抑制小鼠星形胶质细胞活化缓解完全弗氏佐剂所致炎性痛 [J]. 解剖学报, 2024, 55(1): 25-31.
[4]	马婷婷陈建红刘爱翠李海宁. 抑制lncRNA TUG1下调核苷酸结合寡聚结构域样受体蛋白1炎症小体在延缓阿尔茨海默病进展的作用 [J]. 解剖学报, 2024, 55(1): 32-42.
[5]	邹成功冯浩陈兵唐辉邵川孙谋杨荣何家全. 创伤性颅脑损伤中神经功能障碍与认知功能损伤的动态变化 [J]. 解剖学报, 2024, 55(1): 43-48.
[6]	吕海燕沈西雅赵富生朱梅. 松茸多糖对 1-甲基-4-苯基-吡啶离子诱导 PC12 细胞损伤的影响 [J]. 解剖学报, 2024, 55(1): 49-54.
[7]	郑丽平刘霞杜晓华吴亚娟刘珊珊 . 脑源性神经营养因子在牦牛与黄牛端脑不同区域的表达与分布 [J]. 解剖学报, 2024, 55(1): 10-16.
[8]	郝永明郭磊周程辉裴汉军李莉赵哲 . 改良腹主动脉缩窄法建立心肌肥厚模型[J]. 解剖学报, 2024, 55(1): 120-124.
[9]	许亚平余悦欣陈金福王柯柯郭志坤 . 高龄大鼠心室肌间质弹性纤维和胶原纤维的结构分布特征及其机制 [J]. 解剖学报, 2023, 54(6): 716-721.
[10]	王文娟丁雨桐苏昊任捷孙艳荣王涵菲陆嘉莉张林倩白钰秦丽华. 低雌激素状态下大鼠海马及纹状体Nogo-A的表达变化[J]. 解剖学报, 2023, 54(6): 620-627.
[11]	张琴杨俊霞蒋青松. 福辛普利对糖尿病视网膜病变小鼠血管紧张素转化酶2和血管内皮生长因子的影响[J]. 解剖学报, 2023, 54(6): 628-634.
[12]	陈子璇司丽娜舒薇菡张欣魏晨阳程露阳杨松鹤乔跃兵. 褪黑素调控下丘脑PI3K/Akt/mTOR信号延缓雌性小鼠青春期启动的机制 [J]. 解剖学报, 2023, 54(6): 644-651.
[13]	梁盼盼禹爱梅杜静寇文辉王欢欢宋爱霞. 基于c-Jun氨基末端激酶/p38丝裂原活化蛋白激酶信号通路探讨阿魏酸钠对偏头痛大鼠炎症反应的抑制作用[J]. 解剖学报, 2023, 54(6): 652-659.
[14]	徐颖刘斌郑兴何宗钊. 补体C3a受体在盲肠结扎穿孔致脓毒症大鼠认知障碍中的作用及机制 [J]. 解剖学报, 2023, 54(6): 668-675.
[15]	刘哲川李坤马帅男孟家琪王艳芹. 利拉鲁肽对百草枯诱导的小鼠帕金森病模型炎症及线粒体融合/分裂的影响 [J]. 解剖学报, 2023, 54(6): 676-681.

PI3K抑制剂ZSTK474增强水泡性口炎病毒Δ51在骨肉瘤中的抗肿瘤作用

PI3K inhibitor ZSTK474 enhancing the antitumor of vesicular stomatitis virus Δ51 against osteosarcoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价